The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered a third target-specific license under its existing Commercial License Agreement dated October 2016.
This license provides ADC Therapeutics with the rights to Synaffix’s proprietary GlycoConnect™ site-specific antibody-drug conjugation and HydraSpace™ polar spacer technologies to develop and commercialize a third product candidate against a specific target.
The clinical-stage GlycoConnect™ and HydraSpace™ technologies enable best-in-class ADCs with significantly enhanced efficacy and tolerability.
The GlycoConnect conjugation technology exploits the native glycan for site-specific and stable payload attachment and involves proprietary enzymes and metal-free click conjugation components. One key benefit of GlycoConnect is that it has shown to significantly enhance the therapeutic index of an ADC on its own.
HydraSpace™ is a compact and highly polar ADC-enhancing spacer technology which improves the solubility and stability of the payload and the resulting ADC product, thus enhancing further the therapeutic index of the ADC.
Both technologies have demonstrated compatibility with all ADC payload classes and all IgG isotypes and can be applied directly to an existing antibody without any DNA and or protein engineering.
Based on confirmed data the GlycoConnect and HydraSpace-technologies consistently generate ADCs that are more effective and better tolerated when compared to the three major clinical-stage ADC conjugation technologies.
Under the terms of the agreement, Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis.
“We are very pleased with our collaboration, the rapid progress made by ADC Therapeutics and the successive expansion to date,” said Peter van de Sande, Chief Executive Officer of Synaffix.
“This third target-specific license taken out by ADC Therapeutics provides further validation of our ADC technology. Since we reached our license agreement, Synaffix’s GlycoConnect™ and HydraSpace™ technologies have continued to demonstrate their ability to generate exceptional ADC product candidates in terms of therapeutic index,” Van de Sande added.
In January 2019 the first product candidate developed by ADC Therapeutics, using using Synaffix’s technology, reached the clinic. In addition, the company signed commercial license agreements with Mersana Therapeutics and Shanghai Miracogen.
“We look forward to continuing our close collaboration with our license partners, enabling their best-in-class ADCs and expanding our list of collaborations further,” Van de Sande concluded.